© 2026 MJH Life Sciences™ and The Center for Biosimilars - Biosimilars, Health Economics & Insights. All rights reserved.
Laura Joszt, MA
Laura Joszt, MA, is the vice president of content for the managed care and pharmacy brands at MJH Life Sciences®, which includes The American Journal of Managed Care®, Managed Healthcare Executive®, Pharmacy Times®, and Drug Topics®. She has been with MJH Life Sciences since 2011.
Laura has an MA in business and economic reporting from New York University.
Evidence Gaps Continue to Shape Biosimilar Adoption in Pediatric Care
January 05, 2026
Article
There are critical gaps in biosimilar adoption for pediatric patients, focusing on safety, regulatory challenges, and the need for more robust data.
Top 5 Most-Read Policy Articles of 2025
December 22, 2025
Article
In 2025, the latest biosimilar policy developments included bipartisan efforts to enhance affordability and reduce barriers in the pharmaceutical landscape.
First Natalizumab Biosimilar Tyruko Launches, Expanding Access in Multiple Sclerosis
December 18, 2025
Article
Tyruko, the first natalizumab biosimilar for multiple sclerosis, promises significant savings and competition in the US market.
Analysis Highlights Fiscal, Access Benefits of Omalizumab Biosimilars in Europe
September 30, 2025
Article
Omalizumab biosimilars promise significant savings for European health systems, enhancing access to vital therapies for patients with severe allergies.
Australian Study Reveals Significant Cost Savings and Market Impact From Biosimilars
September 10, 2025
Article
Biosimilars significantly reduce health care costs in Australia, enhancing access to biologics while driving price competition in the pharmaceutical market.
SYSA1902 Biosimilar Proves Equivalent to Reference Ustekinumab in Plaque Psoriasis
September 08, 2025
Article
A new biosimilar, SYSA1902, shows comparable efficacy and safety to ustekinumab for treating moderate-to-severe plaque psoriasis, expanding patient options.
What Stands in the Way of Biosimilar Use Across MENA Countries?
May 21, 2025
Article
Despite the clear promise of cost savings and expanded access, the path to integrating generics and biosimilars across the Middle East and North Africa (MENA) region is tangled in a web of distrust, inconsistent policies, and deep-rooted cultural preferences for branded drugs.
Fourth Ustekinumab Biosimilar, Otulfi, Approved in US
September 30, 2024
Article
Otulfi was approved simultaneously in the European Union. In the US, it will launch in February 2025.
Biosimilar Substitution Can Reduce TCOC, Improve Provider Performance in Value-Based Payment Models
December 07, 2023
Article
A simulation study estimated the impact of biosimilar substitution on total cost of care (TCOC) and provider financial performance in the final performance period of the Oncology Care Model.
Payer Controls Limiting Semglee Uptake Despite Patient Demand
July 20, 2023
Article
A new analysis finds branded insulin glargine (Lantus) still has a majority of total market volume and new drug starts despite competition from Semglee, an interchangeable biosimilar.